Document is current
Any future updates will be listed below
-
Authors
Okamura, Ryosuke https://orcid.org/0000-0001-7352-8621
Kato, Shumei
Lee, Suzanna
Jimenez, Rebecca E
Sicklick, Jason K https://orcid.org/0000-0003-4403-0271
Kurzrock, Razelle https://orcid.org/0000-0003-4110-1214
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02478931 at ClinicalTrials.govDocuments that mention this clinical trial
44 Soluble immune markers predict outcome after immune checkpoint blockade in patients with advanced cancers
https://doi.org/10.1136/jitc-2024-sitc2024.0044
EP991 Exceptional response with combined anti-hormone and MEK inhibitor therapy in a patient with hormone receptor-positive ovarian cancer and isolated KRAS alteration. Implications for a precision medicine strategy
https://doi.org/10.1136/ijgc-2019-esgo.1035
<i>ARID1A</i> alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
https://doi.org/10.1136/jitc-2019-000438
Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response.
https://doi.org/10.1200/jco.2024.42.16_suppl.2626
Circulating cell-free DNA as a diagnostic and prognostic marker for cervical cancer
https://doi.org/10.1136/ijgc-2023-004873
-
Funding
Funding for this research was provided by:
The Joan and Irwin Jacobs Fund
NIH (P30 CA023100)
- License Information
